December 22nd, the Japanese news sources, Asahi Shimbun, Livedoor News and many others reported on a significant development regarding cannabis-related products in Japan. The Ministry of Health, Labour and Welfare in Japan has announced a nationwide ban on the manufacture, sale, and advertising of 38 products containing cannabis-like components. This decision comes in response to health issues associated with products like “cannabis gummies.”
The banned substances include a variety of compounds that mimic the effects of cannabis. One such compound, known as HHCH, has been particularly noted for its health risks. The ministry’s action aims to address the growing concerns over these substances, which have been available despite not being officially regulated as cannabis.
This move represents a significant step in Japan’s drug regulation, reflecting a cautious approach towards substances that could pose health risks. The ban on these 38 products is a proactive measure to prevent potential health issues and curb the illegal market of unregulated substances.
For readers residing in legal countries and states, this news highlights the contrasting approaches to cannabis and its derivatives in different parts of the world. While some regions like Canada and parts of the United States have legalized and regulated cannabis, Japan remains strict in its stance against cannabis and related compounds, emphasizing public health and safety. This development could be of interest to those following international drug policy and the varying legal landscapes concerning cannabis and its analogs.
Reference: Yahoo Japan News「大麻類似の38製品販売禁止 厚労省、グミ流通問題で」、Yomiuri Shimbun Online「大麻グミ、厚労省が３８製品を販売禁止…ＨＨＣＨと似た成分を指定薬物に追加の方針」、Asahi Shimbun Digital「大麻の類似成分含む38製品、製造・販売を全国一律禁止 健康被害も」、Livedoor News「大麻類似の38製品、販売や広告を禁止に グミ流通問題で」
